Summary by Moomoo AI
EyePoint Pharmaceuticals announced the appointment of Dr. Reginald J. Sanders, M.D., FASRS, to its Board of Directors effective January 8, 2025. The Board has been expanded to nine members to accommodate this appointment. As a non-employee director, Dr. Sanders will receive an annual cash retainer of $45,000 and an initial stock option grant of 80,000 shares, vesting over three years.Dr. Sanders brings significant expertise as a distinguished retina specialist and the most recent President of the American Society of Retina Specialists. His appointment comes at a crucial time as EyePoint advances its global Phase 3 pivotal trials for wet AMD and recent positive interim data from its Phase 2 trial in diabetic macular edema. Dr. Sanders has served as a principal investigator for...Show More
